Pfizer Soars 19% To All-Time High After Parent Company's Successful Vaccine Trials
Pfizer shares soared nearly 20 per cent to an all-time high on the BSE in early trading after its parent company, the US-based multinational pharma firm Pfizer said that its COVID-19 vaccine, developed in association with the German partner BioNTech SE, was more than 90 per cent effective against SARS-CoV-2, the novel coronavirus that causes Covid-19. Riding on the research developments, the shares of Pfizer opened at the day's and all-time high of Rs 5,875, up as much as 19.5 per cent, on the BSE. At 12:20 pm, the shares pared most of their gains and were trading at Rs 5,100, up 3.7 per cent.
Pfizer and German partner BioNTech have been the first to release data showing that their vaccine worked in large, late-stage clinical trials and said they did not find any serious safety concerns as yet. They will be seeking US emergency use authorization this month.
Drug makers and research centers around the world are racing against time to develop a vaccine to combat the virus, which has already sniffed out countless lives and brought the world economy on its knees. The US-based biotech firm Moderna, Britain-based AstraZeneca-University of Oxford team and Johnson and Johnson are also in advanced stages of phase-3 vaccine trials.
The BSE Sensex was at 43,090.85, higher by 491 points or 1.1 per cent and the NSE Nifty was at 12579.95,up 119.25 points or 0.95 per cent at the time.
-
Extracting Value From Battery Scrap Could Be Challenging For India | The Reason Why
A discarded lithium-ion battery still contains valuable materials such as lithium, nickel and cobalt. These can be recovered and reused. When such batteries are crushed and shredded, they produce a dark powder called black mass.
-
One El Nino, India Can Handle. Two Could Break The Granary
India's grain stocks can absorb one bad year, but a second El Nino could drain the buffer in two to three years, economists say.
-
India's Troika Of Good Luck | Joining The Dots
As Jensen Huang's exit drags Nvidia down, a cooling AI trade and resilient earnings have revived investor interest in India. A likely RBI rate hike looms.
-
Talking Points This Week: Leadership Shock At Nvidia, Earnings Strength, And The Fog Over Hormuz
The Anthropic IPO pricing and first trading day, Nvidia's upcoming earnings, and any fresh signals from Iran will set the tone for the following week.
-
Signature Play: The Classic Cocktail Is Dead. Or Is It?
Classic cocktails are disappearing from India's cocktail menus. But they're still being ordered, taught to bartenders and borrowed from. So, who's really having the last drink?
-
A New Samvat Wishlist: Inclusive Prosperity And Human Development
India has strengthened its economic foundations through infrastructure, digital access and enterprise. Its next growth chapter must deepen productivity, create better livelihoods and widen participation in prosperity.
-
Love, Sex Aur Dhokha: The Audacious Plot To Spy On Jensen Huang
A Taipei dinner, a Singapore chip buyer and a suspected Chinese asset: inside the alleged spy operation that got close to NVIDIA's Jensen Huang.
-
Ten Things I Learnt This Samvat
Patience can be a trap. Cheap stocks can stay cheap. Leverage can wipe you out. What did Samvat 2082 teach us? Niraj Shah writes on 10 lessons from the year gone by.
-
Talking Points This Week: Tech Nerves, FII Buying, And A Faraway Banking Shock
The global markets are not shining this Diwali. The exception in the large markets is, India.
-
Midterm Rally Lasted A Day. The Hard Reality Of A Divided US May Last Two Years | Opinion
Between a contested AI boom, a debt ceiling that arrives in 2027 and a president with every incentive to act alone, the next two years may prove more volatile than the first day's rally suggests.